ClinicalTrials.gg
TerminatedNCT04976127NEONUpdated Apr 22, 2026

Safety Evaluation of Intravenous Talineuren (TLN) in Parkinson's Disease-affected Patients

A Phase 1 interventional study of Talineuren in Parkinson Disease, sponsored by InnoMedica Schweiz AG. Terminated at 1 site in Switzerland. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by InnoMedica Schweiz AG · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Treatment stopped earlier due to Verfügung Swissmedic. Safety visits in the end of the trial still were carried out (LPLV 06.08.2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Non-randomized
Ages
30 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Parkinson Disease with a site in Switzerland — 31 open to participants now, 34 under way, none of them phase 3. Parkinson Disease · Switzerland.

Enrollment
40th of 67
22 · median 30
Started
2021
with 10 others
Phase 1
4 of 85
none open now
Registered
47th of 85
by date

Among the 85 studies in Parkinson Disease with a site in Switzerland, this one is the 40th largest by enrollment of the 67 interventional ones that give a count, is one of 11 that started in 2021, is one of 4 in phase 1, and was the 47th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

31 of the 85 studies in Parkinson Disease with a site in Switzerland are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Parkinson Disease with a site in Switzerland, or all of them as a file.
02

Study summary

This study is an open-label, single ascending dose escalation followed by a multiple administration dose at the maximal suitable dose (MSD). The investigational Medicinal Product (IMP) is given as an add-on therapy.

Talineuren consists of GM1 (monosialotetrahexosylganglioside), the pharmacologically active ingredient, associated with a proprietary lipid formulation assembled as liposomes.

The primary objective is to demonstrate the safety of TLN administration intravenously in Parkinson patients.

Secondary objectives are the determination of the maximal suitable dose based on the safety profile and preliminary efficacy, as well as the determination of the pharmacokinetics (PK) profile.

Read the detailed description

The ganglioside lipid GM1 has been described in the literature as a neuroprotective agent.

Several clinical studies have shown that GM1 improves the condition of Parkinson's disease patients.

Talineuren consists of the pharmacologically active ingredient GM1, associated with a proprietary lipid formulation assembled as liposomes. Talineuren has been developed to improve the delivery and bioavailability of GM1.

The primary objective of this trial is to demonstrate the feasibility and safety of intravenous Talineuren administration in Parkinson's disease patients.

The secondary objectives are:

  • The determination of the recommended phase 2 dose based on the safety profile and preliminary efficacy.
  • The determination of the pharmacokinetics (PK) profile.

This trial aims to investigate the safety of the novel formulation of GM1, Talineuren.

To that extent a three-part trial was designed: Part 1- Dose escalation Part 2- Dose consolidation Part 3- Dose consolidation with intrapatient dosing

Part 1- rapid dose escalation scheme from 6 mg to 720 mg of Talineuren formulated GM1 in 3 patients. Optional treatment prolongations for 8 weeks (Amendment 1), 16 weeks (Amendment 2), 8 months (Amendment 3), 4 months (Amendment 4), and 12 months (Amendment 5).

Part 2- multiple dosing of Talineuren over 8 weeks in 9 patients to validate the safety profile of the maximum suitable dose. Optional treatment prolongations for 16 weeks (Amendment 2), 8 months (Amendment 3), 4 months (Amendment 4), and 12 months (Amendment 5).

Part 3- rapid dose escalation scheme from 6 mg to 720 mg of Talineuren followed by multiple doses of 720mg Talineuren for up to 8 months in 10 patients (Amendment 3). Additional Follow-up visit (washout timepoint) 4 months after final assessment (Amendment 6).

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
30 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • as documented by signature.
  • Confirmed Parkinson's disease according to British brain bank criteria.
  • Hoehn and Yahr Stage 0 - 2.5 on medication.
  • Stable on PD treatment for a month at least.
  • Absence of dementia confirmed by cognitive testing ( >25).

Exclusion criteria

Exclusion Criteria:

  • to the class of drugs under study, e.g., known or allergy to class of drugs or the product.
  • Women who are pregnant or breast feeding, or planning to become pregnant during the course of the trial or in the 3 months following the trial.
  • Lack of safe in women with
  • Other concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc) that is not under stable control.
  • Subject has an atypical parkinsonian syndrome or secondary parkinsonism.
  • Patients with comorbidity that may interfere with the course of the trial.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Talineuren dose escalation

    14 doses of GM1 Ganglioside 6, 12, 60, 120, 180, 240, 300, 360, 420, 480, 540, 600, 660, 720 mg. Optional treatment prolongations for 16 weeks (Amendment 2), 8 months (Amendment 3), 4 months (Amendment 4) and 12 months (Amendment 5).

    Drug: Talineuren

  • Experimental
    Talineuren repeated dose

    8 repeated doses of GM1 Ganglioside tbd from the escalation dose (maximum suitable dose). Optional treatment prolongations for 16 weeks (Amendment 2), 8 months (Amendment 3), 4 months (Amendment 4) and 12 months (Amendment 5).

    Drug: Talineuren

  • Experimental
    Talineuren dose consolidation with intrapatient dosing (additional patients)

    8 months repeated doses of 720mg GM1 Ganglioside (Amendment 3).

    Drug: Talineuren

Interventions

  • DrugTalineuren

    Talineuren is a liposomal formulation of the GM1 Ganglioside for intravenous administration

    Also known as: liposomal GM1

06

What researchers measure

Primary outcomes

  1. Occurence of adverse events (safety)

    Number and kinds of adverse events (AEs)

    Time frame: 8 to 134 weeks

  2. Occurence of serious adverse events (safety)

    Number and kinds of serious adverse events (SAEs)

    Time frame: 8 to 134 weeks

  3. Occurence of other safety-related signs (safety)

    Number and kinds of other safety-related signs

    Time frame: 8 to 134 weeks

Secondary outcomes

  1. Levodopa challenge (LDC) test

    Assessing the patients' condition via the LDC test (MDS-UPDRS-3 score)

    Time frame: 8 to 134 weeks

  2. Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)

    Assessing the patients' condition via the test

    Time frame: 8 to 134 weeks

  3. Epworth Sleepiness Scale (ESS)

    Assessing the patients' condition via the test

    Time frame: 8 to 134 weeks

  4. Parkinson's Disease Questionnaire (PDQ-39)

    Assessing the patients' condition via the test

    Time frame: 8 to 134 weeks

  5. Change in Parkinson's medication

    Assessing the patients' condition via the change in their pre-existing Parkinson's medication

    Time frame: 8 to 134 weeks

  6. Starkstein Apathy Scale (SAS)

    Assessing the patients' condition via the test

    Time frame: 8 to 134 weeks

  7. Montreal Cognitive Assessment (MoCA)

    Assessing the patients' condition via the test

    Time frame: 8 to 134 weeks

  8. Beck's Depression Inventory (BDI)

    Assessing the patients' condition via the test

    Time frame: 8 to 134 weeks

  9. Non-Motor Symptoms Questionnaire (NMSQuest)

    Assessing the patients' condition via the test

    Time frame: 8 to 134 weeks

  10. Maximum Observed Drug Concentration (Cmax) in serum

    Pharmacokinetics (PK) of total GM1 in serum over the first 96 h

    Time frame: 8 to 15 weeks

  11. Time of Maximum Drug Concentration (Tmax) in serum

    Pharmacokinetics (PK) of total GM1 in serum over the first 96 h

    Time frame: 8 to 15 weeks

  12. Area Under the Curve to infinity (AUCinf.) in serum

    Pharmacokinetics (PK) of total GM1 in serum over the first 96 h

    Time frame: 8 to 15 weeks

  13. half-life (t1/2)

    Pharmacokinetics (PK) of total GM1 in serum over the first 96 h

    Time frame: 8 to 15 weeks

  14. Clearance (CL)

    Pharmacokinetics (PK) of total GM1 in serum over the first 96 h

    Time frame: 8 to 15 weeks

  15. Volume of distribution (Vd)

    Pharmacokinetics (PK) of total GM1 in serum over the first 96 h

    Time frame: 8 to 15 weeks

07

Study locations

1 site
  • Neurologisches Institut Konolfingen
    Konolfingen, Canton of Bern 3510, Switzerland
08

References and documents

Publications

  • Halbherr S, Lerch S, Bellwald S, Polakova P, Bannert B, Roumet M, Charles RP, Walter MA, Bernasconi C, Halbherr VL, Peitsch C, Baumgartner PC, Kaufmann C, Aires V, Mattle HP, Kaelin-Lang A, Hartmann A, Schuepbach M. Safety and tolerability of intravenous liposomal GM1 in patients with Parkinson disease: A single-center open-label clinical phase I trial (NEON trial). PLoS Med. 2025 May 13;22(5):e1004472. doi: 10.1371/journal.pmed.1004472. eCollection 2025 May. PubMed 40359409 ↗
  • Roy R, Paul R, Bhattacharya P, Borah A. Combating Dopaminergic Neurodegeneration in Parkinson's Disease through Nanovesicle Technology. ACS Chem Neurosci. 2023 Aug 16;14(16):2830-2848. doi: 10.1021/acschemneuro.3c00070. Epub 2023 Aug 3. PubMed 37534999 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Aug 2025, 43 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2021
First posted
Jul 26, 2021
StartActual
Dec 11, 2021
Primary completionActual
Aug 6, 2025
CompletionActual
Aug 6, 2025
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04976127
Lead sponsor
InnoMedica Schweiz AG
Responsible party
Sponsor
First posted
Jul 26, 2021
Start date
Dec 11, 2021
Primary completion
Aug 6, 2025
Completion
Aug 6, 2025
Last update
Apr 22, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion